Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Rivaroxaban with Cobicistat and Darunavir/Cobicistat in Healthy Volunteers
NCT03864406Phase 1Completed
- Sponsor
- National Institutes of Health
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rivaroxaban in thromboembolic disorders, sponsored by National Institutes of Health. Primary endpoints: Area Under the Concentration Versus Time Curve from zero to infinity at Day 13, Area Under the Concentration Versus Time Curve from 0 to 24 hours and 6 more. Started Jun 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolic disorders
Beyond the preview
Go deeper on NCT03864406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864406.